Increasing awareness and knowledge of Alpha-gal Syndrome in the United States
Centers for Disease Control - NCEZID
About this archived opportunity
The purpose of this NOFO is to improved awareness and knowledge of alpha-gal syndrome (AGS) in the United States. AGS is an emerging condition and is not nationally notifiable. This NOFO seeks to improve AGS surveillance, patient care, and public awareness and understanding. The NOFO strategies are to 1) SHARE - Formation of a network of AGS professionals to disseminate latest knowledge of AGS among stakeholders, including public health agencies, academic researchers, and advocacy groups, in order to improve patient care for AGS and the public health response. 2) EDUCATE - Create AGS communications targeted at the general public, AGS patients, or persons at higher risk for tick encounters (outdoor enthusiasts, dog owners, outdoor workers, etc.). Create communications targeted at healthcare providers including educational resources and training. 3) TRACK - Conduct active or enhances public health surveillance for AGS. This strategy could involve patient populations or geographical locations with limited access to specialized healthcare provider care.
Historical details
- Status
- Closed
- Deadline
- July 9, 2026
- First captured
- December 12, 2025
- Award
- $25,000 - $1,000,000
- Publisher reference
- 360958
Eligibility: Bona fide agents are eligible to apply. For more information about bona fide agents, please see the CDC webpage on Expediting the Federal Grant Process with an Administrative Partner located at https://www.cdc.gov/publichealthgateway/grantsfunding/expediting.html#Q2
This opportunity has closed
Increasing awareness and knowledge of Alpha-gal Syndrome in the United States
by Centers for Disease Control - NCEZID
Get notified when similar opportunities open
We'll save this search and email you when new increasing, awareness, knowledge opportunities are posted. Free.
Related opportunities
- Reissue of RFA-FD-22-001 - Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01 Clinical Trials Optional)Food and Drug AdministrationCloses Feb 2028Up to $600K
- Animal Food Regulatory Program Standards Implementation Development and Maintenance, with Mutual Reliance Initiatives Clinical Trials Not AllowedFood and Drug AdministrationCloses Apr 2027Up to $300K
- Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)National Institutes of HealthCloses Nov 2026
- Natural History of Disorders Screenable in the Newborn Period (R01 Clinical Trial Optional)National Institutes of HealthCloses Jan 2028